CALL US +44 (0)1462 440 084 | +1 919-882-2016 | Contact | Submit RFI

The Trend in Biosimilar Development and Recent FDA Guidance

Statistical Consultancy Team

At the present time, the regulatory and drug development communities are adapting to a rising trend in biosimilar development in a number of therapeutic areas.

The regulatory framework for biosimilars in the US is still evolving; the number of biosimilars approved by the FDA in 2015 was 1, this rose to 4 in 2016 and is set to increase in 2017. The FDA is developing and consulting on draft guidance documents that will shape future trials, and at this early stage there are a number of legal issues to be agreed around licencing conditions, such as the period of exclusivity and the applicability of the biosimilar to all approved indications of the reference product. To put this in context with the European landscape, biosimilars have been approved and used in the EU for over a decade without highlighting any major safety concerns. As of April 2017, there were 28 approved biosimilars in the EU on 11 different biologics. However, there are aspects of the emerging FDA guidance that will almost certainly be reflected in the evolution of trial designs in the future, for products aimed at the US market.

Read More
Topics: Regulatory Requirements, Pharmacokinetics and Pharmacodynamic, FDA, Clinical Study Design, European Medicines Agency, Bioequivalence, PK Analysis, Demonstrating Biosimilarity, Biosimilars

The Creation of ADaM Datasets for Pharmacokinetic (PK) Analysis [Video]

Clinical Programming Team

In this recorded presentation a member of the Quanticate's Statistical Programming Team explores the creation of two ADaM datasets; ADPC and ADPP for Pharmacokinetic (PK) Analysis.

 

Read More
Topics: Pharmacokinetics and Pharmacodynamic, CDISC Guidelines, CDISC SDTM, SDTM Domains, CDISC, Clinical Programming, SDTM, CDISC Standards, PK Analysis, ADaM Datasets

Performing CDISC Compliant Pharmacokinetic Analyses

Statistical Consultancy Team

 

The Clinical Data Interchange Standards Consortium (CDISC) is a global not-for-profit organization that develops standards to support the acquisition, exchange, submission, and archive of data in clinical research. The mission of CDISC is to develop and support global, platform-independent data standards that enable information system interoperability to improve medical research and related areas of healthcare.

Read More
Topics: Statistical Programming, Pharmacokinetics and Pharmacodynamic, CDISC SDTM, CDISC, SDTM, Bioequivalence, PK Analysis, ADaM Datasets

Pharmacokinetic Considerations of Biosimilars

Statistical Consultancy Team

When faced with the prospect of proving pharmacokinetic “equivalence” of a biosimilar to an innovator biologic, it may be natural to assume that standard bioequivalence study designs and analysis methods would be sufficient to meet the objectives of the study; after all, such study designs have been successfully employed for many years to bring generic drugs to market. However, there are a number of characteristics of biologics which set them apart from traditional generic drugs, as summarised in Table 1, below.

Read More
Topics: Pharmacokinetics and Pharmacodynamic, Bioequivalence, PK Analysis, Demonstrating Biosimilarity, Biosimilars

SAS Business Intelligence - A Perceptive Vision in Clinical Trials

Clinical Programming Team
Tables, listings and figures are part of day to day clinical submissions. Hence it would be useful if statisticians/clients could easily analyse the study data through different time points. This allows for better decisions because you are able to view outputs while the study is on going, this visualisation during a study can allow for great efficiencies as decisions can be made earlier in the clinical trial.
Read More
Topics: Statistical Programming, CDISC SDTM, SDTM Domains, CDISC, SAS Programming, SDTM, PK Analysis, Visualization, SAS BI, SAS Business Intelligence, SAS Web Report Studio

PK data analysis and reporting: SAS or Phoenix WinNonlin?

Statistical Consultancy Team

 

  

SAS [1] is regarded as the industry standard for clinical data analysis and reporting; however, Phoenix WinNonlin[2], which is a powerful tool tailored to the specific demands of PK data, is widely accepted as the industry standard for PK data analyses. This widespread separation of responsibilities, and the resultant transfer of data between software applications (and in many cases departments), has the potential to not only cause significant reporting delays, but can also lead to incohesive clinical study reports (CSRs) containing tables, listings and figures (TLFs) derived from various different sources.

Read More
Topics: Pharmacokinetics and Pharmacodynamic, Clinical Study Report, SAS Programming, Biostatistics Consulting, PK Analysis

Welcome to The Quanticate Blog

We aim to provide information and support written by our experienced staff. We want to share our knowledge and create an archive of information that you will be able to engage with, share and comment on.

Subscribe to Email Updates

Blog Suggestions

Posts by Topic

Expand all